Ankylosing Spondylitis is an inflammatory disease that can cause problems in spine. This usually causes inflammation in spine which can cause chronic pain and discomfort. It can also fuse vertebrae in the spine which can make the spine less flexible. In some cases this also can form new bone in the spine which can cause sections of the spine to fuse in an immobile or fixed position. This disease is most likely to be occurred in the people with gene called HLA- B27. This condition can cause some other complications such as eye inflammation, heart problems, compression fractures and other. Practically there is no cure for this condition but some medication and treatment can be done so that there sign and symptoms can be reduced. Different drugs such as TNF blockers, anti- inflammatory drugs, immunosuppressive drugs, nonsteroidal anti- inflammatory drugs and other are given to the patient with this condition.
Access Full Report at https://www.databridgemarketresearch.com/reports/global-ankylosing-spondylitis-as-market
Some of the factors responsible for the growth of this market are as follow:
The global ankylosing spondylitis (AS) market is segmented on the basis of drug type as nonsteroidal anti-inflammatory drugs, tnf blockers, immunosuppressive drugs, anti-inflammatory drugs, steroids, jak inhibitors, and others; application as juveniles, & adults; molecule as biologics, biosimilars,& small molecules and route of administration as parenteral, and oral.
Some of the launches and acquisition in the market are as follow:
“According to Data Bridge Market Research, global ankylosing spondylitis market is set to witness a substantial CAGR in the forecast period of 2019 to 2026”
Few of the major competitors currently working in the global ankylosing spondylitis (AS) market are Merck & Co., Inc., AbbVie Inc., Reliance Life Sciences., Xian Janssen Pharmaceutical Ltd., Momenta Pharmaceuticals, Sandoz International GmbH, Pfizer Inc., Amgen Inc., Regeneron Pharmaceuticals, CELGENE CORPORATION, Trinity Biotech Ireland, Sanofi, Novartis AG, F. Hoffmann-La Roche Ltd, Eisai Co., Ltd., Celltrion Inc., Boehringer Ingelheim International GmbH, Hetero, Izana Bioscience and others
Today, many people are demanding for the treatment of this ankylosing spondylitis as it causes them pain and discomfort. Government is also taking many different steps and initiatives so they can provide better healthcare infrastructure. Many different medications are available in the market for the treatment of this disease.
Global Ankylosing Spondylitis (AS) Market – Industry Trends & Forecast to 2026